Loading...
Header Logo
Keywords
Last Name
Institution
 Back to Details

Connection

Peter Friedmann to Buprenorphine

This is a "connection" page, showing publications Peter Friedmann has written about Buprenorphine.

 
Connection Strength
  
 
 
3.354
  
  1. Andrews CM, D'Aunno TA, Pollack HA, Friedmann PD. Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs. Med Care Res Rev. 2014 Feb; 71(1):43-60.
    View in: PubMed
    Score: 0.560
  2. D'Aunno T, Pollack HA, Jiang L, Metsch LR, Friedmann PD. HIV testing in the nation's opioid treatment programs, 2005-2011: the role of state regulations. Health Serv Res. 2014 Feb; 49(1):230-48.
    View in: PubMed
    Score: 0.553
  3. Friedmann PD, Hoskinson R, Gordon M, Schwartz R, Kinlock T, Knight K, Flynn PM, Welsh WN, Stein LA, Sacks S, O'Connell DJ, Knudsen HK, Shafer MS, Hall E, Frisman LK. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012; 33(1):9-18.
    View in: PubMed
    Score: 0.497
  4. Friedmann PD, Jiang L, Alexander JA. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs. J Behav Health Serv Res. 2010 Jul; 37(3):322-37.
    View in: PubMed
    Score: 0.410
  5. Stein MD, Friedmann PD. Optimizing opioid detoxification: rearranging deck chairs on the Titanic. J Addict Dis. 2007; 26(2):1-2.
    View in: PubMed
    Score: 0.352
  6. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005 Nov; 20(11):1038-41.
    View in: PubMed
    Score: 0.324
  7. Park TW, Friedmann PD. Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders. R I Med J (2013). 2014 Oct 01; 97(10):20-4.
    View in: PubMed
    Score: 0.150
  8. Zaller N, McKenzie M, Friedmann PD, Green TC, McGowan S, Rich JD. Initiation of buprenorphine during incarceration and retention in treatment upon release. J Subst Abuse Treat. 2013 Aug; 45(2):222-6.
    View in: PubMed
    Score: 0.135
  9. Taylor LE, Maynard MA, Friedmann PD, Macleod CJ, Rich JD, Flanigan TP, Sylvestre DL. Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy? J Addict Med. 2012 Sep; 6(3):179-85.
    View in: PubMed
    Score: 0.130
  10. Friedmann PD, Schwartz RP. Just call it "treatment". Addict Sci Clin Pract. 2012; 7:10.
    View in: PubMed
    Score: 0.128
  11. Stein MD, Herman DS, Kettavong M, Cioe PA, Friedmann PD, Tellioglu T, Anderson BJ. Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. J Subst Abuse Treat. 2010 Sep; 39(2):157-66.
    View in: PubMed
    Score: 0.112
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.